Who are the Institutional Holders in Revance Therapeutics Inc (RVNC)?

Revance Therapeutics Inc (NASDAQ: RVNC) is -38.34% lower on its value in year-to-date trading and has touched a low of $5.00 and a high of $37.98 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RVNC stock was last observed hovering at around $5.38 in the last trading session, with the day’s gains setting it 0.04%.

Currently trading at $5.42, the stock is -6.09% and -22.85% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.67 million and changing 0.74% at the moment leaves the stock -67.91% off its SMA200. RVNC registered -84.35% loss for a year compared to 6-month loss of -73.19%. The firm has a 50-day simple moving average (SMA 50) of $3.10 and a 200-day simple moving average (SMA200) of -$1.97.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


The stock witnessed a -22.90% gain in the last 1 month and extending the period to 3 months gives it a -36.90%, and is 5.24% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.78% over the week and 9.00% over the month.

Revance Therapeutics Inc (RVNC) has around 534 employees, a market worth around $475.93M and $214.16M in sales. Profit margin for the company is -193.42%. Distance from 52-week low is 8.40% and -85.73% from its 52-week high. The company has generated returns on investments over the last 12 months (-114.06%).

Revance Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.72 with sales reaching $62.63M over the same period.The EPS is expected to grow by 17.25% this year, but quarterly earnings will post 71.10% year-over-year. Quarterly sales are estimated to grow 25.50% in year-over-year returns.

265 institutions hold shares in Revance Therapeutics Inc (RVNC), with institutional investors hold 104.79% of the company’s shares. The shares outstanding are 82.39M, and float is at 78.11M with Short Float at 18.95%. Institutions hold 94.83% of the Float.

The top institutional shareholder in the company is Capital World Investors with over 9.57 million shares valued at $242.34 million. The investor’s holdings represent 10.89% of the RVNC Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 6.53 million shares valued at $165.19 million to account for 7.42% of the shares outstanding. The other top investors are Palo Alto Investors Lp which holds 5.23 million shares representing 5.94% and valued at over $132.34 million, while JP Morgan Chase & Company holds 5.34% of the shares totaling 4.69 million with a market value of $118.8 million.

Revance Therapeutics Inc (RVNC) Insider Activity

A total of 10 insider transactions have happened at Revance Therapeutics Inc (RVNC) in the last six months, with sales accounting for 6 and purchases happening 4 times. The most recent transaction is an insider sale by Moxie Dwight, the company’s SVP, GC & Secretary. SEC filings show that Moxie Dwight sold 11,000 shares of the company’s common stock on Sep 06 at a price of $17.06 per share for a total of $0.19 million. Following the sale, the insider now owns 44066.0 shares.

Revance Therapeutics Inc disclosed in a document filed with the SEC on Sep 05 that Moxie Dwight (SVP, GC & Secretary) sold a total of 23,853 shares of the company’s common stock. The trade occurred on Sep 05 and was made at $17.81 per share for $0.42 million. Following the transaction, the insider now directly holds 55066.0 shares of the RVNC stock.

Still, SEC filings show that on Aug 03, Foley Mark J (CEO) disposed off 26,279 shares at an average price of $22.57 for $0.59 million. The insider now directly holds 840,375 shares of Revance Therapeutics Inc (RVNC).

Revance Therapeutics Inc (RVNC): Who are the competitors?

One of the company’s main competitors (and peers) include Ionis Pharmaceuticals Inc. (IONS) that is trading 28.15% up over the past 12 months.Biogen Inc. (BIIB) lies in the list of competitors of the Revance Therapeutics Inc and is -16.07% lower over the same period from RVNCJohnson & Johnson (JNJ) is -3.55% down on the 1-year trading charts.